Sofwave Receives FDA Clearance for Pure ImpactTM in Strengthening and Firming of Arms in the U.S
Approval to Market Sofwave™ in South Korea
Date
Key Regulatory Milestone in Company’s International Growth Strategy for Unrivaled Ultrasound Technology Treating Fine Lines and Wrinkles
YOQNEAM, Israel, Aug. 30, 2021 /PRNewswire/ — Sofwave Medical LTD, today announced it has received approval from the Korean Ministry of Foods and Drug Safety (MFDS) to market Sofwave™ its proprietary next-generation Synchronous Ultrasound Parallel Beam technology SUPERB™ for reducing the appearance of fine lines and wrinkles while also revitalizing the skin.
Sofwave’s state-of-the-art Synchronous Ultrasound Parallel Beam technology SUPERB™ addresses the growing demand for non-invasive treatments that deliver noticeable wrinkle reduction. The device’s seven cooled transducers are directly coupled to the epidermis, creating a unique 3D array of volumetric thermal zones that deliver parallel energy simultaneously, heating precisely at the right depth in the mid-dermis to improve the overall appearance. A single Sofwave treatment reduces facial wrinkles in a fast 30 to 45minute non-invasive treatment with no interruption to a patient’s daily routine or post-treatment discomfort.
